...
首页> 外文期刊>Perspectives in Clinical Research >Comparison of efficacy and safety of topical 1% nadifloxacin and tretinoin 0.025% combination therapy with 1% clindamycin and tretinoin 0.025% combination therapy in patients of mild-to-moderate acne
【24h】

Comparison of efficacy and safety of topical 1% nadifloxacin and tretinoin 0.025% combination therapy with 1% clindamycin and tretinoin 0.025% combination therapy in patients of mild-to-moderate acne

机译:局部1%Nadifloxacin和三丙氨酸的疗效和安全性的疗效和安全性与1%Clindamycin和Tretinain 0.025%组合治疗的疗效和维甲酰胺患者患者温和至中等痤疮患者的组合治疗

获取原文
           

摘要

Background: Topical retinoids in combination with antimicrobials have been proven to reduce acne lesions faster and to a greater degree than antimicrobial therapy alone . Aims and Objectives: To compare the efficacy and safety of topical combination of 1% Nadifloxacin [NAD] and 0.025% Tretinoin [Tr] with 1% Clindamycin [CLN] and 0.025% Tr in patients of mild to moderate acne vulgaris of the face. Material and Methods: There were two groups (40 patients in each group): Group A received (NAD+Tr) combination therapy and group B received (CLN+Tr) combination therapy. Efficacy was assessed by any reduction in the mean number of inflammatory lesions(IL), non-inflammatory lesions(NIL) and/or total lesions(TL) as well as by using Evaluator's Global Severity Scale (EGSS) of acne and safety was assessed by adverse effects of study medications at 0, 6 and at 12 weeks follow-up. Results: Both the study groups showed statistically significant intragroup reduction in NIL, IL and TL after 12 weeks of therapy. There was no statistically significant reduction at the end of 6 weeks of therapy in both the groups. At the end of 12 weeks of therapy there was a statistically significant reduction in IL, NIL and TL in group A. There was no statistically significant difference in the occurrence of adverse effects in both the groups. Conclusion: Overall the study proved better efficacy of NAD+Tr compared to CLN+Tr. Medications of both the groups were safe and well tolerated.
机译:背景:已被证明与抗微生物组合的局部类视黄曲面,以更快地减少痤疮病变,并且比单独的抗微生物治疗更大程度。目的和目标:将1%Nadifloxacin [NAD]和0.025%TretinoIn [Tr]的局部组合与0.025%Tr]与0.025%Tr在轻度至中等痤疮紫色的患者中的局部组合和0.025%Tr的疗效和安全性。材料和方法:有两组(每组40例患者):A组接受(NAD + TR)组合治疗和B组接受(CLN + TR)组合治疗。通过炎症病变(IL)的平均数量,非炎性病变(NIL)和/或总病变(TL)以及使用评估员的全球严重程度(EGS)进行评估,评估疗效评估疗效。评估痤疮和安全性通过研究药物在0,6和12周随访时对研究药物的不利影响。结果:研究组均在治疗12周后均有统计学显着的Intragrous intrage,Intractous Intragrous intract组。在两组群体中,在6周的治疗结束时没有统计学显着减少。在疗法12周结束时,IL,NIL和TL中存在统计学显着的减少,A组中的TL统计学显着降低。群体中的不良反应没有统计学显着差异。结论:与CLN + TR相比,该研究证明了NAD + TR的更好疗效。两组的药物都是安全和良好的耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号